Lucentis获批，糖尿病性视网膜病变患者的福音！

Search Product

Structure Search

Search

Online Support

Customer service

Advantage Products

Adefovir Dipivoxil Intermediates

2-Aminothiazole

Di-p-xylylene

5-Bromo-4-chloro-3-indolyl phosphate p-toluidine salt

N-Cyclohexyl-3-aminopropanesulfonic acid

(±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid

Nitrotetrazolium blue chloride

3-(2-Spiroadamantane)-4-methoxy-4-(3-phosphoryloxy)phenyl-1,2-dioxetane

N-[2-(diethylamino)ethyl]acrylamide

POLYQUATERNIUM-1

4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid(HEPES)

Tris

3,3',5,5'-Tetramethylbenzidine

Trometamol

Trometamol

4-BROMO-2-THIOPHENECARBOXALDEHYDE

Guanidine hydrochloride

IPTG

Guanidine isothiocyanate

Location: Industrial Info

Lucentis was approved to treat all types of diabetic retinopathy

2017-04-18 来源：转载自第三方

18 April 2017

On April 17, 2017, FDA approved Lucentis (ranibizumab injection, 0.3mg) from Genentech (a member of Roche Group) for the treatment of all types of diabetic retinopathy. This approval has made Lucentis the first and only drug to treat all types of diabetic retinopathy.

Diabetes is a serious chronic disease and is an important public health problem. Over the past few decades, the number and prevalence of diabetes have steadily increased. According to statistics from World Health Organization last year, there are about 400 million patients with diabetes around the world. The terrible aspect of diabetes is not its own, but the disease can affect other parts of the body, causing complications such as retinopathy, kidney disease, neuropathy and coronary artery, cerebrovascular and peripheral vascular disease, it is a serious threat to health.

Due to high blood sugar, retinal blood vessels of diabetic patients will be damaged, causing a series of fundus lesions. Diabetic retinopathy is one of the common complications of diabetic patients, it is also the number one killer in the elderly. Although there are more than a dozen hypoglycemic agents, including sulfonylurea drugs, such as glibenclamide, glimepiride, glipizide and tolbutamide; thiazolidinedione drugs such as pioglitazone and rosiglitazone; SGLT-2 inhibitors such as Canagliflozin, Jardiance and Dapagliflozin; DPP-4 inhibitors such as sitagliptin or vildagliptin (intermediate 3-Amino-1-adamantanol); biguanides, such as metformin, but drugs can significantly improve the microcirculation and circulation of drugs is not much.

Lucentis is a humanized therapeutic antibody fragment, the active ingredient ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor which is designed to block all biologically active forms of vascular endothelial growth factor A (VEGF-A). The level of VEGF-A is elevated in diseases such as wet age-related macular degeneration (AMD), retinal vein occlusion macular edema (RVO), and diabetic macular edema (DME). In large clinical studies, Lucentis injections have improved the condition, regardless of whether patients have had DME, and it has no new safety problems.

Since 2006, Lucentis has been approved for the following indications in Europe: wet age-related macular degeneration (wet-AMD), pathologic myopia (PM) secondary choroidal neovascularization (CNV) Diabetic macular edema (DME), retinal branch vein occlusion (BRVO), visual impairment caused by omentum central venous obstruction (CRVO).

Lucentis was approved by FDA to be the first and only anti-VEGF therapy approved for the treatment of all types of diabetic retinopathy, providing a effective treatment for retinal complications for the majority of people with diabetes. We also hope that more drugs can be listed to improve the living quality of patients with diabetes, and prolong their life-span.